BROWN RUDNICK LLP for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act Issues relating to Risk Evaluation and Mitigation Strategies and implementation of the Generic Drug User Fee Act
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN New | Prof Staff, House Cmte on Ed & Workforce 99-01 |
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
Pharmacy PHA
H.R. 3204: The Drug Quality and Safety Act S. 959: The Pharmaceutical Quality, Security and Accountability Act
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN New | — |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.